Remodeling of glucose metabolism precedes pressure overload-induced left ventricular hypertrophy: Review of a hypothesis

Cardiology (Switzerland)

Volumn 130, Issue 4, 2015, Pages 211-220

  Kundu, Bijoy K ^a,c   Zhong, Min ^a,b   Sen, Shiraj ^d   Davogustto, Giovanni ^d   Keller, Susanna R ^a   Taegtmeyer, Heinrich ^d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b Departments of Physics   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

2 deoxy 2 18F fluoro D glucose positron emission tomography; Endoplasmic reticulum stress; Glucose 6 phosphate; Left ventricular hypertrophy; Mechanistic target of rapamycin activation

Indexed keywords

FLUORODEOXYGLUCOSE; GLUCOSE 6 PHOSPHATE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PROPRANOLOL; RAPAMYCIN; 2-DEOXY-2-FLUORO-3-O-METHYLGLUCOSE; 3 METHYLGLUCOSE; ANTIDIABETIC AGENT; FATTY ACID; TARGET OF RAPAMYCIN KINASE;

EARLY INTERVENTION; ENDOPLASMIC RETICULUM STRESS; EX VIVO STUDY; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART VENTRICLE REMODELING; HUMAN; IN VIVO STUDY; INTERVENTION STUDY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; ANALOGS AND DERIVATIVES; ANIMAL; COMPLICATION; DISEASE MODEL; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART VENTRICLE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT;

3-O-METHYLGLUCOSE; ANIMALS; DISEASE MODELS, ANIMAL; ENDOPLASMIC RETICULUM STRESS; FATTY ACIDS; GLUCOSE-6-PHOSPHATE; HEART FAILURE; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; HYPOGLYCEMIC AGENTS; METFORMIN; MICE; MYOCARDIUM; POSITRON-EMISSION TOMOGRAPHY; RATS; SIROLIMUS; TOR SERINE-THREONINE KINASES; VENTRICULAR FUNCTION, LEFT;

EID: 84925431313     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000369782     Document Type: Review

References (48)

1. Go AS, Mozaffarian D, Roger VL, et al: Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013; 127:e6-e245.
2. Katz AM: Cardiomyopathy of overload-a major determinant of prognosis in congestive heart failure. N Engl J Med 1990; 322: 100-110.
3. Bishop SP, Altschuld RA: Increased glycolytic metabolism in cardiac hypertrophy and congestive failure. Am J Physiol 1970; 218: 153-159.
4. Taegtmeyer H, Hems R, Krebs HA: Utilization of energy-providing substrates in the isolated working rat heart. Biochem J 1980; 186: 701-711.
5. Allard MF, Schonekess BO, Henning SL, et al: Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol 1994; 267:H742-H750.
6. Goodwin GW, Taylor CS, Taegtmeyer H: Regulation of energy metabolism of the heart during acute increase in heart work. J Biol Chem 1998; 273: 29530-29539.
7. Young ME, Yan J, Razeghi P, et al: Proposed regulation of gene expression by glucose in rodent heart. Gene Regul Syst Bio 2007; 1: 251-262.
8. Taegtmeyer H, Golfman L, Sharma S, et al: Linking gene expression to function: metabolic flexibility in the normal and diseased heart. Ann NY Acad Sci 2004; 1015: 202-213.
9. De las Fuentes L, Soto PF, Cupps BP, et al: Hypertensive left ventricular hypertrophy is associated with abnormal myocardial fatty acid metabolism and myocardial efficiency. J Nucl Cardiol 2006; 13: 369-377.
10. Doenst T, Pytel G, Schrepper A, et al: Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload. Cardiovasc Res 2010; 86: 461-470.
11. Zhong M, Alonso CE, Taegtmeyer H, et al: Quantitative PET imaging detects early metabolic remodeling in a mouse model of pressure-overload left ventricular hypertrophy in vivo. J Nucl Med 2013; 54: 609-615.
12. Sen S, Kundu BK, Wu HC, et al: Glucose regulation of load-induced mTOR signaling and ER stress in mammalian heart. J Am Heart Assoc 2013; 2:e004796.
13. Taegtmeyer H: Cardiac metabolism as a target for the treatment of heart failure. Circulation 2004; 110: 894-896.
14. Lopaschuk GD: Optimizing cardiac fatty acid and glucose metabolism as an approach to treating heart failure. Semin Cardiothorac Vasc Anesth 2006; 10: 228-230.
15. Kolwicz SC Jr, Tian R: Metabolic therapy at the crossroad: how to optimize myocardial substrate utilization? Trends Cardiovasc Med 2009; 19: 201-207.
16. Gropler RJ, Beanlands RS, Dilsizian V, et al: Imaging myocardial metabolic remodeling. J Nucl Med 2010; 51(suppl 1):88S-101S.
17. Taegtmeyer H: Tracing cardiac metabolism in vivo: one substrate at a time. J Nucl Med 2010; 51(suppl 1):80S-87S.
18. Osterholt M, Sen S, Dilsizian V, et al: Targeted metabolic imaging to improve the management of heart disease. JACC Cardiovasc Imaging 2012; 5: 214-226.
19. Gropler RJ: Recent advances in metabolic imaging. J Nucl Cardiol 2013; 20: 1147-1172.
20. Gallamini A, Zwarthoed C, Borra A: Positron emission tomography (PET) in oncology. Cancers (Basel) 2014; 6: 1821-1889.
21. Zhong M, Kundu BK: Optimization of a model corrected blood input function from dynamic FDG-PET images of small animal heart in vivo. IEEE Trans Nucl Sci 2013; 60: 3417-3422.
22. Sharma S, Guthrie PH, Chan SS, et al: Glucose phosphorylation is required for insulin-dependent mTOR signalling in the heart. Cardiovasc Res 2007; 76: 71-80.
23. Proud CG: Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy. Cardiovasc Res 2004; 63: 403-413.
24. Neubauer S, Krahe T, Schindler R, et al: 31 P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 1992; 86: 1810-1818.
25. Neubauer S, Horn M, Pabst T, et al: Contributions of 31 P-magnetic resonance spectroscopy to the understanding of dilated heart muscle disease. Eur Heart J 1995; 16(suppl O):115-118.
26. Beanlands RS, Nahmias C, Gordon E, et al: The effects of beta(1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: a double-blind, placebo-controlled, positron-emission tomography study. Circulation 2000; 102: 2070-2075.
27. Hasegawa S, Kusuoka H, Maruyama K, et al: Myocardial positron emission computed tomographic images obtained with fluorine-18 fluoro-2-deoxyglucose predict the response of idiopathic dilated cardiomyopathy patients to beta-blockers. J Am Coll Cardiol 2004; 43: 224-233.
28. Brooks WW, Shen SS, Conrad CH, et al: Transition from compensated hypertrophy to systolic heart failure in the spontaneously hypertensive rat: structure, function, and transcript analysis. Genomics 2010; 95: 84-92.
29. Bing OH, Brooks WW, Robinson KG, et al: The spontaneously hypertensive rat as a model of the transition from compensated left ventricular hypertrophy to failure. J Mol Cell Cardiol 1995; 27: 383-396.
30. Brooks WW, Conrad CH, Robinson KG, et al: L-Arginine fails to prevent ventricular remodeling and heart failure in the spontaneously hypertensive rat. Am J Hypertens 2009; 22: 228-234.
31. Kato T, Niizuma S, Inuzuka Y, et al: Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ Heart Fail 2010; 3: 420-430.
32. Hernandez AM, Huber JS, Murphy ST, et al: Longitudinal evaluation of left ventricular substrate metabolism, perfusion, and dysfunction in the spontaneously hypertensive rat model of hypertrophy using small-animal PET/CT imaging. J Nucl Med 2013; 54: 1938-1945.
33. Nguyen VT, Mossberg KA, Tewson TJ, et al: Temporal analysis of myocardial glucose metabolism by 2-[ 18 F]fluoro-2-deoxy-D-glucose. Am J Physiol 1990; 259:H1022-H1031.
34. Roberts DJ, Tan-Sah VP, Ding EY, et al: Hexokinase-II positively regulates glucose starvation-induced autophagy through TORC1 inhibition. Mol Cell 2014; 53: 521-533.
35. Brunken R, Schwaiger M, Grover-McKay M, et al: Positron emission tomography detects tissue metabolic activity in myocardial segments with persistent thallium perfusion defects. J Am Coll Cardiol 1987; 10: 557-567.
36. Depre C, Vanoverschelde JL, Melin JA, et al: Structural and metabolic correlates of the reversibility of chronic left ventricular ischemic dysfunction in humans. Am J Physiol 1995; 268:H1265-H1275.
37. Bolukoglu H, Goodwin GW, Guthrie PH, et al: Metabolic fate of glucose in reversible low-flow ischemia of the isolated working rat heart. Am J Physiol 1996; 270:H817-H826.
38. Goodwin GW, Arteaga JR, Taegtmeyer H: Glycogen turnover in the isolated working rat heart. J Biol Chem 1995; 270: 9234-9240.
39. Russell RR III, Cline GW, Guthrie PH, et al: Regulation of exogenous and endogenous glucose metabolism by insulin and acetoacetate in the isolated working rat heart. A three tracer study of glycolysis, glycogen metabolism, and glucose oxidation. J Clin Invest 1997; 100: 2892-2899.
40. Saha AK, Xu XJ, Lawson E, et al: Downregulation of AMPK accompanies leucine-and glucose-induced increases in protein synthesis and insulin resistance in rat skeletal muscle. Diabetes 2010; 59: 2426-2434.
41. Glembotski CC: The role of the unfolded protein response in the heart. J Mol Cell Cardiol 2008; 44: 453-459.
42. Mochizuki T, Tsukamoto E, Ono T, et al: Sequential change of BMIPP uptake with age in spontaneously hypertensive rat model. Ann Nucl Med 1997; 11: 299-306.
43. Locke LW, Berr SS, Kundu BK: Image-derived input function from cardiac gated maximum a posteriori reconstructed PET images in mice. Mol Imaging Biol 2011; 13: 342-347.
44. Fang YH, Muzic RF Jr: Spillover and partialvolume correction for image-derived input functions for small-animal 18 F-FDG PET studies. J Nucl Med 2008; 49: 606-614.
45. Wallhaus TR, Taylor M, Degrado TR, et al: Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 2001; 103: 2441-2446.
46. Taylor M, Wallhaus TR, Degrado TR, et al: An evaluation of myocardial fatty acid and glucose uptake using PET with [ 18 F]fluoro-6-thia-heptadecanoic acid and [ 18 F]FDG in patients with congestive heart failure. J Nucl Med 2001; 42: 55-62.
47. Ellis JM, Mentock SM, Depetrillo MA, et al: Mouse cardiac acyl coenzyme A synthetase 1 deficiency impairs fatty acid oxidation and induces cardiac hypertrophy. Mol Cell Biol 2011; 31: 1252-1262.
48. Ekeruo IA, Solhpour A, Taegtmeyer H: Metformin in diabetic patients with heart failure: safe and effective? Curr Cardiovasc Risk Rep 2013; 7: 417-422.